1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)

Abstract

1,25 (OH)2 D3 has been shown to be able to reduce the growth of several human cell lines.

The effect of 1,25 (OH)2 D3 on the growth of breast cancer cell lines in relation to their oestrogen (ER) and progesterone (PGR) receptor content has been investigated.

The growth inhibition of BT-20 and MCF-7 cell lines is related to the dose of 1,25 (OH)2 D3.

It is dependent on the foetal calf serum concentration in the culture medium.

At low concentration of 1,25 (OH)2 D3 the inhibitory effect is not detectable in the presence of 10% FCS. The rescue of cells from inhibition by serum was less effective when 1,25 (OH)2 D3 was present in the medium.

The results of [3H]thymidine incorporation experiments and DNA measurements are in agreement with the reduction of cell number. Analysis in flow cytometry indicated a reduced number of cells in S phase.

These data indicate that 1,25 (OH)2 D3 is able to modulate the growth of human breast adenocarcinoma cells regardless of their sex steroid dependency.

About this publication.

See also:

- Vitamin D (analogues and/or derivatives) and cancer;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.